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4 Pulmonary hypertension due to acute respiratory distress syndrome (ARDS) or primary pulmonary hypertension of the newborn (PPHN) represent imbalanced homeostasis of vasoconstrictor and vasodilator peptides controlling pulmonary artery pressure (Keith, 2000) .
Pulmonary hypertension is associated with increased expression of endothelin-1 (ET-1), a potent constrictor, in pulmonary vascular endothelial cells. The local production of endothelin-1 is assumed to contribute to the vascular abnormalities associated with this disorder (Giaid et al., 1993) . Adrenomedullin (ADM) is a potent vasodilator peptide. In the lung, ADM was shown to be present in several cells, such as endothelial and smooth muscle cells, alveolar macrophages and the columnar epithelium (Jougasaki and Burnett, Jr., 2000) . ADM receptors are highly expressed in lung and heart tissue. Analysis of the ADM binding sites suggests a regulatory role of the peptide for the pulmonary circulation and cell differentiation (Kapas et al., 1995; Owji et al., 1995) . ADM preferentially reduces pulmonary artery pressure through a decrease of pulmonary vascular resistance (Cheng et al., 1994; Lippton et al., 1994; Heaton et al., 1995) . The marked elevation of ADM plasma levels in patients with pulmonary hypertension may represent a compensatory mechanism (Kakishita et al., 1999) . Intravenous infusion of ADM in adult patients with precapillary pulmonary hypertension reduces the pulmonary vascular resistance significantly. However, systemic vascular resistance is simultaneously decreased (Nagaya et al., 2000) . Similar systemic effects are seen with the application of ADM into the pulmonary artery of fetal sheep (Takahashi et al., 1999) . Although pulmonary hypertension may respond to systemic vasodilator therapy, the treatment frequently fails because intravenous administration of vasodilators may increase blood flow in non-ventilated lung areas, increasing the ventilation/perfusion mismatch. In addition adverse effects on the systemic blood pressure are This article has not been copyedited and formatted. The final version may differ from this version. (Agusti and Rodriguez-Roisin, 1993) . Administration of therapeutic drugs via inhalation is supposed to be more selective for the pulmonary vascular bed. This has been shown for inhaled nitric oxide (Nagamine et al., 2000; Demirakca et al., 1996) and for inhaled prostacyclin (Olschewski et al., 1999) . To date, no studies on the efficacy and pulmonary selectivity of aerosolized ADM in pulmonary hypertension have been performed.
We therefore examined the impact of aerosolized ADM on pulmonary artery pressure, systemic arterial pressure, and oxygenation in neonatal piglets with acute respiratory distress syndrome and pulmonary hypertension.
Intravenous infusion of ADM (50 ng/kg/min) showed significant effects after 15 minutes (Nagaya et al., 2000) . Hence, in the present intervention 30 minutes inhalation intervals with incremental doses of ADM, followed by 30 minutes observation were used. This article has not been copyedited and formatted. The final version may differ from this version. 
METHODS

Research animals:
Seventeen piglets of both sexes with a body weight of 3,5-4,3 kg were included in the study.
The study was approved by the Animal Care Committee of the University of Erlangen and the government of Mittelfranken, Germany, and performed according to guidelines of the NIH. Animals randomly received aerosolized ADM (ADM, n=6), aerosolized ADM combined with intravenous application of N G -nitro-L-arginine methylester to inhibit nitric oxide synthases (ADM+L-NAME, n=5), or aerosolized normal saline solution (control, n=6).
After a venous catheter had been placed into an ear vein, anesthesia was induced with midazolam (1 mg/kg), fentanyl (2,5 µg/kg) and ketamine (5 mg/kg) followed by continuous infusion of midazolam (1.5 mg/kg per hour), fentanyl (0.01 mg/kg per hour) and ketamine (15 mg/kg per hour) (Kandler et al., 2001; von der Hardt et al., 2002b) . Piglets generally require high doses of anesthetics for narcosis. Therefore, the combination of three anesthetics was used. It was the intention to prevent adverse effects such as hyperthermia that occurs e.g. 
Study protocol:
Lung injury with pulmonary hypertension was induced by surfactant depletion (repeated saline lung lavage (NaCl 0.9%, temperature 39 °C) using 30 ml/kg per side (Kandler et al., 2001; Lachmann et al., 1980) . Piglets where included if lung injury was considered to be stable, defined as PaO 2 constantly remaining below 80 mmHg for a period of sixty minutes.
If inclusion criteria failed, repeated lung lavages were performed until criteria had been met.
During instrumentation and for the duration of the experiment, animals were in supine position. The animals were randomly assigned to three different therapy groups (adrenomedullin, ADM+L-NAME and control). In all animals, respiratory support was 8 intervals over a total period of 5 hours (volume rate of 4 ml/h). The observation was continued for three hours after the inhalation procedure. To investigate the role of NO formation in the mechanism of ADM effects, NO synthases were inhibited in the ADM+L-NAME group. Piglets additionally received the inhibitor of the nitric oxide synthases L-NAME (Sigma, Steinheim, Germany) at a dose of 25 mg/kg/h intravenously 30 min before and continuously during the 8 h of the experiment. Piglets in the Control group received aerosolized saline solution (4 ml/h). After an additional observation period of 3 hours, animals were sacrificed by intravenous injection of 50 mg/kg methohexital and 20 ml potassium chloride 7.46%. Lungs and heart were removed en bloc.
Tissue processing:
The left lung was perfused with 5% buffered paraformaldehyde. For histological examinations from standardized sites, samples were taken from the peripheral upper and lower lobe. 5µm thick sections of paraffin embedded tissue sections were stained with hematoxylin-eosin for routine histo-pathologic evaluation. Chloracetate esterase histochemic reaction was performed to visualize neutrophil granulocytes. One blinded expert pathologist examined the sections for the items hyaline membranes, hyperemia, interstitial edema, intraalveolar hemorrhage and neutrophil accumulation and attributed each item to a 4-point score:
0: None, 1: mild, 2: moderate and 3: severe. Lung injury score was calculated including all sites and items (Quintel et al., 1998) . For each site, the score of all items was summarized.
Data are presented as mean ± SEM of this summary score including all the sites.
RT-PCR
Standardized specimens (four from the inferior lobe (central and basal), two from the superior and two from the middle lobe) were taken from the native peripheral right lung and stored at -80°C until mRNA extraction was performed using guanidine-thiocyanate acid phenol Efficiency and reliability of this method have been shown earlier (Dötsch et al., 1999; Heid et al., 1996; Schoof et al., 2002) . The use of TaqMan real time PCR in this animal model was recently published (von der Hardt et al., 2002b; . Primers and TaqMan probes were elected for the porcine model (Table 1 ). This approach is based upon the 5' exonuclease activity of the Taq polymerase. Briefly, within the amplicon defined by a gene specific oligonucleotide primer pair an oligonucleotide probe labeled with two fluorescent dyes is designed. As long as the probe is intact, the emission of a reporter dye (i.e. 
RESULTS
Mean pulmonary artery pressure
Bronchoalveolar lavage increased MPAP from 15.8 ± 1.1 mmHg to 37.5 ± 2.3 mmHg in the ADM, from 14.3 ± 0.9 mmHg to 38.8 ± 2.0 mmHg in the ADM+L-NAME group and from 16.0 ± 1.7 to 37.2 ± 2.2 mmHg in the saline control group (these post lavage values were defined as baseline). Aerosolized ADM reduced mean pulmonary artery pressure (MPAP) significantly compared to the control group (at the end of the study: (ADM) 21.5 ± 2.0 vs.
(control) 28.7 ± 1.5 mmHg; p<0.001, Fig. 1 ). In addition, the decline of MPAP was significantly steeper in the ADM than in the control group. In animals continuously treated with L-NAME MPAP fell to 29.4 ± 2.1 mmHg (at the end of the study). Looking at the reduction of MPAP from the baseline of each group, ADM effect was unchanged when L-NAME was infused simultaneously (Fig. 1) . The difference from baseline MPAP was significant after 2.5 hours in the ADM group and could not be distinguished from baseline before 4.5 hours in the control group.
Mean arterial pressure
During administration of aerosolized ADM and throughout the observation period, systemic mean arterial pressure (MAP) was not influenced compared to baseline ( Fig. 2 and Fig. 3 ).
There was no significant difference in MAP between the ADM and the control group (Fig. 3) .
In contrast, L-NAME increased MAP significantly and maintained higher levels throughout the course of the experiment (p<0.001; Fig. 3 ).
This article has not been copyedited and formatted. The final version may differ from this version. 
Arterial oxygen tension:
Compared to the baselines (after establishment of pulmonary hypertension), PaO 2 significantly increased in the ADM group (p<0.01) and in the ADM+L-NAME group (p<0.01, Fig. 4) . The arterial oxygen tension in both groups was significantly higher than in the control group (p<0.001). There was no significant difference in PaO 2 between the ADM and the ADM+L-NAME group during the treatment and the post treatment observation period (Fig. 4) .
NO Synthases
iNOS mRNA expression was slightly but significantly lower in the ADM and the ADM+L-NAME group compared to the control group (p<0.05). These results were obtained irrespectively of whether gene expression was normalized to the housekeeping genes ß-actin or HPRT (Fig. 5) . eNOS mRNA expression was significantly lower in the ADM group than in the control group only when normalized to ß-actin (p< 0.01; Fig. 5 ). eNOS mRNA expression was significantly lower in the ADM+L-NAME group than in the control group when normalized to both, ß-actin and HPRT (p< 0.01; Fig. 5 ).
Endothelin-1
ET-1 mRNA gene expression was significantly reduced after treatment with aerosolized ADM compared to the control group (reduction: ET-1/A: 62.4% , ET-1/HPRT: 51.0%, p<0.001; 14
DISCUSSION
The present study demonstrates a sustained decrease of MPAP by the repeated administration of aerosolized ADM (25 to 100 ng/kg/min) whereas mean systemic arterial pressure remained unchanged. This is markedly different from literature showing a significant reduction of systemic arterial pressure in addition to the intended reduction of pulmonary pressure when ADM was applied intravenously. The lower doses (6.25 and 12.5 ng/kg/min) did not show a significant effect ( Fig. 1 and Fig. 2 ). In our study, a considerable improvement of oxygenation was observed by ADM inhalation. This suggests a sustained beneficial effect on ventilation perfusion mismatch, that is well known to be an important component of pulmonary vascular disease (Agusti and Rodriguez-Roisin, 1993) . Similar effects were observed after inhalation of various vasodilators like nitric oxide, iloprost and sodium nitroprusside (Demirakca et al., 1996; Schutte et al., 2001; Olschewski et al., 1999) .
The positive effect of ADM on pulmonary vascular resistance might be even enhanced or perpetuated by the improvement of oxygenation. As histology of representative pulmonary specimens did not show significant differences between the groups, it seems unlikely that changes in lung injury led to consecutive reduction of vascular resistance. As far as safety issues are concerned, there were no expected or unexpected side effects of the therapy. In particular, none of the animals died during the use of inhaled ADM. Instead, an antiinflammatory effect of inhaled ADM could be demonstrated by reduction of transforming growth factor-ß1 and interleukin-1ß gene expression (von der Hardt et al., 2002a) . In prior studies, the vasodilating effect of ADM has been shown to be -at least in part -mediated by activation of nitric oxide synthases and enhancement of iNOS expression (Feng et al., 1994) .
Under physiological conditions, the ADM effect on pulmonary vascular resistance can be attenuated by NOS inhibitor administration to fetal sheep (Takahashi et al., 1999) . (Dötsch et al., 2002) . In our present series of experiments, L-NAME did not attenuate the beneficial effect of inhaled ADM on pulmonary vasodilation and oxygenation. In addition, ADM did not increase iNOS gene expression. The reduced gene expression of iNOS and eNOS does not necessarily reflect enzyme activity.
Nonetheless, it can be concluded from the L-NAME experiment that ADM does not work exclusively via NO synthase activation or expression. The fact that L-NAME does not influence ADM induced vasodilatation in this study implies that ADM might predominantly act via other pathways. For future experiments it might be useful to assess the effect of L-NAME on pulmonary arterial resistance in comparison to L-NAME+ADM. The effect of ADM might be mediated via the transmembrane ADM receptor by an increase in intracellular cyclic AMP concentration (Ishizaka et al., 1994; Shimekake et al., 1995) , which is vasorelaxant itself (Maurice and Haslam, 1990) . Furthermore, cAMP might impede the function of phosphodiesterase IIIa, which is responsible for the decay of cyclic GMP, the most important mediator of nitric oxide induced vasodilation (Shah and Kadowitz, 2002) , this mechanism mimics NO mediated vasodilatation. To prove the specific intrapulmonary ADM effect manipulation of ADM receptor function e.g. by the infusion or inhalation of a specific antagonist such as ADM 22-52 might be included in future studies.
The reduction of ET-1 mRNA gene expression, following treatment with aerosolized ADM might be mediated by the suppressive effect of cAMP on ET-1 synthesis (Magnusson et al., 1994) . Therefore, the vasorelaxant effect of ADM might be potentiated by the reduction of ET-1 synthesis. It appears unlikely that the mechanism of ADM action is via an increased activity of prostaglandins or is exerted by activation of calcitonin gene related peptide receptor (Takahashi et al., 1999) .
This article has not been copyedited and formatted. The final version may differ from this version. Recently, a number of publications have addressed the systemic use of ADM in humans for the correction of various hemodynamic disorders. Apart from the improvement of pulmonary hypertension (Nagaya et al., 2000) , cardiac afterload could be reduced (Del Bene et al., 2000) . Interestingly the vascular effects of ADM are significantly attenuated in patients with chronic heart failure, in part because of impaired production of nitric oxide (Nakamura et al., 1997 ). In our model, animals have experienced serious pulmonary damage before the onset of ADM inhalation with probably severe impairment of NO synthases. Therefore, the effect of ADM on pulmonary artery pressure of newborn piglets might be even more pronounced if NO synthases function was maintained at a normal level. Nonetheless, the studies in humans are encouraging towards a potential use of inhaled ADM in man.
CONCLUSION
Aerosolized adrenomedullin leads to improved oxygenation, a reduction in ET-1 gene expression, and a selective reduction in pulmonary artery pressure, without lowering the systemic blood pressure.
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